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REVISTA BRASILEIRA
DE HEMATOLOGIA
E  H E M O T E R A P I A
Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms
that are derived from post-thymic lymphoid cells at different stages of differentiation
and with different morphological patterns, phenotypes, and clinical presentations. PTCLs
are highly diverse, reflecting the diverse cells from which they can originate and are
currently sub-classified using World Health Organization (WHO) 2008 criteria.
Peripheral T-Cell Lymphomas account for 5%-10% of all lymphoproliferative disorders
in the Western hemisphere, with an overall incidence of 0.5-2 per 100,000 individuals
per year, and have a striking epidemiological distribution, with higher incidence in
Asia. The clinical features of PTCL are extremely heterogeneous. PTCLs express even
more clinical diversity than B-cell non-Hodgkin's lymphomas, and there is a close,
though not absolute, relationship between some unusual clinical features and certain
histological subtypes. Rev. Bras. Hematol. Hemoter. 2009;31(Supl. 2):21-25.
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Introduction
Despite efforts to transfer the most recent advances in
the treatment of other subtypes of B-cell lymphomas to
patients with T-cell lymphomas (PTCL), the prognosis of
patients with PTCL is still poor and, unfortunately, the optimal
therapy for PTCL is still unknown. The complete response
rate is rather low, ranging from 40% to 50% with a median
relapse free survival (RFS) of 2-3 years. As a consequence of
the aggressiveness of the disease and of the low efficacy of
available salvage treatments, overall survival (OS) is also
short and the long-term survival rate is lower than 10% in
many series. Several studies have been performed to assess
the contribution of a number of clinical and biological factors
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to the prognosis of PTCL.8,11-17 In most of them, adverse
prognostic features such as poor performance status,
advanced stage, presence of extranodal sites, bulky disease,
and high LDH levels were significantly correlated with shorter
OS. The usefulness of the International Prognostic Index
(IPI), defined for Diffuse Large B-Cell Lymphomas (DLBCLs)
has also been investigated and confirmed by several authors.
To better define the clinical outcome of PTCL-not
otherwise specified (PTCL-NOS), the Intergruppo Italiano
Linfomi (IIL) performed a large study of 385 patients
diagnosed and treated in the 1990s and defined a prognostic
model specifically devised for patients with this uncommon
disease.14 Among different clinical parameters assessed at
time of diagnosis, age (< 60 years), performance status (ECOG
PS 2 or higher), LDH level above upper normal range, and
bone-marrow involvement were identified as independent
predictors in OS. In addition to defining a prognostic model
specifically devised for PTCL-NOS, the IIL study underlined
the need for cooperation among researchers in order to
develop rationally designed and potentially more-efficacious
treatment modalities.
More recently, the role of biological features of the
disease is emerging as an important issue not only to
understand its pathogenesis but also for prognosis and to
address specific biological targets altered in the neoplasm.
The expression of Th1- or Th2-associated antigens or
activated T-cell receptors, for example, has been recently
evaluated in a series of T-NHLs. The pattern of expression of
such antigens was correlated with the specific subtype of
nodal T-cell lymphoma (AITL, ALCL, and PTCL-NOS) and
allowed the identification of subgroups of PTCL-NOS
patients with different probabilities of survival.18 In particular,
patients with PTCL-NOS expressing one of Th1 or Th2
antigens tended to show favorable prognoses as compared
with cases not expressing Th1 or Th2 antigens.
Significant progress in the prognosis of PTCL can be
expected from the novel, sophisticated, and powerful
technologies of genomics and proteomics, which will allow
more reliable sub-typing of PTCL into distinct clinical groups
characterized by different patterns of survival.19-22
In 2003 the International T-Cell Lymphoma Project
started a broad cooperative study aiming at better defining
the clinicopathologic features and prognoses of different
neoplastic entities included some in the group of PTCLs and
NKTCLs. A cohort of 1,314 cases was collected from 22
centers worldwide, consisting of patients with previously
untreated PTCL or NKTCL who were diagnosed between
1990 and 2002. This was the largest series reported to date of
peripheral NK/T-cell lymphomas. The results recently
published confirm that the clinical outcome for patients with
most of these lymphoma subtypes is poor with standard
therapies and novel agents and new modalities being needed
23
to improve survival.23 In the same cohort of patients, analyses
of single subsets were also carried out, with the publication,
so far, of three additional papers focusing on specific
subtypes. Particularly, analyses carried out on ALK negative
ALCL suggest that they have to be considered as peculiar
entities with clinical and immunophenotypic characteristics
that differ in form to those of both ALK-positive ALCL and
PTCL-NOS.24 In the group of 126 patients diagnosed with
aggressive ATLL, the role of the International Prognostic
Index in predicting outcome was confirmed.25 Finally
investigations performed on a subset of 136 patients with
extranodal NKTCL show that clinical features and treatment
response of extra-nasal NK/T-cell lymphoma are different from
those of nasal lymphoma, and that their OS is significantly
poorer.26
One common limitation of studies on prognosis of PTCL
is their retrospective nature. Currently available data are based
on analysis performed on a series collected over a long period
of time. This aspect is very important as it may introduce
relevant biases in the collected series. First, classification
systems have changed dramatically over time and cases may
have been defined in different ways based on period of
diagnosis. Second, some clinical or laboratory data which
now are considered of potential prognostic relevance may
have not been determined in older series of patients. Third,
in a retrospective analysis there is no guarantee that collected
series are based on real consecutive cases.
The T- cell project
Given that all clinical trials and retrospective studies
conducted so far underline the difficulty of diagnosing these
tumors accurately and stress that currently available therapies
are ineffective in many subtypes, in 2006 the International T-
Cell Lymphoma Project thought it would be useful to start a
new study based on the prospective registration over a short
period of time of patients with peripheral T-cell lymphoma for
whom it would be possible to collect an exhaustive set of
clinical data and biological information. In fact, the
retrospective study allowed the International T-Cell
Lymphoma Project to create an international network of
collaboration between different Institutions. This network -
considering the rarity of the disease - is essential to develop
and carry out the new clinical studies that are needed in
order to improve the clinical and therapeutic approach to
PTCLs.
This project, called the "T-Cell Project" opened
registration of patients on September 1, 2006, with the aim of
collecting a cohort of 1,000 patients diagnosed with Peripheral
T-Cell Lymphoma. The T-Cell Project is designed as a
prospective collection of information potentially useful to
predict the prognosis of newly diagnosed patients with the
more frequent subtypes of peripheral T-cell lymphoma
(Peripheral T-cell lymphoma not otherwise specified and
angioimmunoblastic T-cell lymphoma) and to better define
clinical characteristics and outcomes of the more uncommon
subtypes.
Patients eligible for the study are those satisfying the
following inclusion criteria: previously-untreated patients
diagnosed with peripheral T-cell or NK/T-cell lymphoma
according to WHO 2001 classification27 since September 1,
2006; age over 18; tissue biopsies adequate for diagnosis
and classification and available for centralized review; clinical
data including baseline information on disease localization
and laboratory parameters at staging, features of treatment
adopted and assurance of follow-up updating for at least 5
years for living patients. Participating Institutions are asked
to provide a consecutive series of cases, without any
selection, once permission is obtained from the Institutional
Review Board and/or the Scientific Review Committee as
required by individual institutional policies. Patients can be
included in the project after giving their written informed
consent, regardless of their planned treatment (observation
only included). Registration is based on locally established
histological diagnosis; a panel of expert hematopathologists
is planned to review diagnosis of all patients entered in the
study. Patient registrations are performed using a dedicated
SSL-protected website (www.tcellproject.org) accessible to
each investigator by requesting a personal account.
The purpose of the T-Cell Project is to verify whether a
prognostic collection of data would result in more accurate
information to better define prognosis and to investigate the
most adequate treatment strategies for these neoplasms. The
main endpoint is 5-year overall survival, the secondary
endpoint 5-year event free survival. Additional endpoints
are remission rate with initial therapy and 5-year progression
free survival.
Due to the fact that prognosis has to be studied in the
two most frequent subtypes of PTCLs - PTCL-NOS and AITL
- the sample size is calculated based on characteristics of
these two subtypes. The T-Cell project aims to accrue 460
patients diagnosed with PTCL-NOS and 460 patients
diagnosed with AITL. Since the definition of a sample size
for more uncommon PTCLs subtypes is not possible due to
their rarity, the study is designed only to prospectively collect
all cases of rarer histologies in the same time frame as PTCL-
NOS and AITL are planned to be accrued. Based on the final
accrual of the former retrospective International PTCL study,
the success of the F2-study (that prospectively collected
1,093 patients with follicular lymphoma in 2 years 28) and the
interest in the project expressed by participants of both of
these previous studies, it was originally planned to complete
accrual in 2 years.
So far 418 patients have been included in the T-Cell
Project. The accrual is a bit under expected due mainly to the
lengthiness of procedures needed to achieve authorization
by Institutional Review Boards/Ethics Committees of centers
willing to take part in the project. Some new institutions have
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been authorized in the study in the last six months, and some
additional ones submitted the request and will soon join in
the project. Currently, 13 countries contributed to the accrual.
Brazil joined the T-cell Project in February 2009, and so far
several patients have been registered. Given this prolonged
phase of center activation in the project, the planned accrual
will be completed by the end of 2010 (4 years from study
opening).
Differently from what was expected, PTCL-NOS account
for 153 cases (36.6%) out of 418 and angioimmunoblastic for
only 66 cases (15.8%). So the angioimmunoblastic cohort is
about half of what was planned. The remaining 199 patients
were diagnosed as reported in Table 2.
The T-Cell Project also encourages the collection and
the storage at local centers of fresh frozen samples – tumor,
serum and mononuclear peripheral cells – for possible further
analyses (to be performed at the end of registration period),
which are planned to be performed if a consistent number of
samples is put together.
Recently, an epidemiologic sub-study has been
associated to the T-Cell project. In fact, although a number of
case-control studies on non-Hodgkin's lymphoma (NHL) have
identified various risk factors for disease, including
autoimmune conditions, family history of hematopoietic
malignancies, smoking, hepatitis C infection, and host
susceptibility, these risk factors largely pertain to B-cell
lymphoma subtypes as they comprise well over 90% of all
NHLs. At present, there are no known epidemiologic risk
factors for PTCL or its subtypes. This is largely due to the
lack of sample size of PTCL in any one epidemiologic study.
So we considered worthy to include an epidemiologic
component to the planned prospective enrollment of PTCLs,
realizing that its resources would be further enhanced by the
addition of standardized information on risk factors for PTCLs.
Indeed, current clinical trials of T-cell lymphomas are not
systematically collecting detailed information on patients'
family history of cancer, medical and medication history
unrelated to the cancer diagnosis and treatment, smoking
habits, pesticide exposure, etc. Because many of these factors
are significantly associated to risk of NHL, the addition of
epidemiologic data to existing clinical and pathologic
information would generate unique opportunities to improve
our understanding of PTCL etiology and prevention.
Conclusion
In conclusion, the T-Cell Project highlights the
importance of international cooperation, which is imperative
when studies are focused on rare diseases such as T-cell
lymphomas. Only such efforts will allow new trials to carry
out biological investigations to define biological features of
each subtype and possibly develop specific and more
efficacious therapies for these neoplasms.
Resumo
Linfomas T periféricos (PTCLs) compreendem um grupo hetero-
gêneo de neoplasias que derivam das células linfoides pós-tímicas
nos diversos estágios de maturação, com diversos padrões histo-
lógicos, fenotípicos, e clínicos. PTCLs são muito diversos entre si
e refletem diversas células das quais foram originadas e são atual-
mente subclassificadas, usando-se a classificação da Organização
Mundial da Saúde (OMS) 2008, apresentada neste texto na tabela
1. PTCLs compreendem 5%-10% de todas as doenças linfo-
proliferativas no mundo ocidental, com uma incidência global de
0.5 a 2 a cada 100.000 pessoas por ano e têm uma distribuição
epidemiológica diversa com maior incidência na Ásia. Os achados
clínicos dos PTCLs são muito heterogêneos. PTCLs expressam
muito maior variação de apresentações clínicas do que os linfomas
B, e há uma íntima, mas não absoluta, relação entre algum achado
clínico não usual e certos subtipos histológicos. O autor faz aqui
uma revisão do assunto altamente contemporâneo Rev. Bras.
Hematol. Hemoter. 2009;31(Supl. 2):21-25.
Palavras-chave: Linfomas-T; evolução; quimioterapia; epide-
miologia.
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